Psychotropic drugs

Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third Edition

Volumn , Issue , 2015, Pages 293-339

  Wisner, Katherine L ^a   Schaefer, Christof ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antidepressants; Antipsychotics; Anxiolytics; Hypnotics; Mood stabilizers; Neuroleptics; Parkinson drugs; Pregnancy; Restless legs; Sedatives; SGA; SSRI

Indexed keywords

EID: 84943243922     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-408078-2.00012-3     Document Type: Chapter

References (238)

1. ACOG Obesity in pregnancy http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Obstetric_Practice/Obesity_in_Pregnancy.
2. Aichhorn W., Yazdi K., Kralovec K., et al. Olanzapine plasma concentration in a newborn. J Psychopharmacol 2008, 22:923-924.
3. Alwan S., Reefhuis J., Botto L.D., et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010, 203:52-56.
4. Alwan S., Reefhuis J., Rasmussen S.A., et al. National Birth Defects Prevention Study: Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356:2684-2692.
5. Alwan S., Reefhuis J., Rasmussen S.A., et al. National Birth Defects Prevention Study: Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 2011, 51:264-270.
6. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000, 58:19-36.
7. Andrade S.E., McPhillips H., Loren D., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009, 18:246-252.
8. Ang M.S., Thorp J.A., Parisi V.M. Maternal lithium therapy and polyhydramnios. Obstet Gynecol 1990, 76:517-519.
9. Ansorge M.S., Morelli E., Gingrich J.A. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008, 28:199-207.
10. Babu G.N., Desai G., Tippeswamy H., Chandra P.S. Birth weight and use of olanzapine in pregnancy: a prospective comparative study. J Clin Psychopharmacol 2010, 30:331-332.
11. Bakker M.K., Kerstjens-Frederikse W.S., Buys C.H., et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010, 88:94-100.
12. Barker D.J., Osmond C., Golding J., et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989, 298:564-567.
13. Bar-Oz B., Einarson T., Einarson A., et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 2007, 29:918-926.
14. Bartfai Z., Kocsis J., Puho E.H., et al. A population-based case-control teratologic study of promethazine use during pregnancy. Reprod Toxicol 2008, 25:276-285.
15. Bellantuono C., Tofani S., Di Sciascio G., Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview 2013, 35:3-8.
16. Benoit R. Does lithium exposure warrant referral for fetal echocardiogram?. Am J Obstet Gynecol 2004, 191:S127.
17. Bérard A., Ramos E., Rey E., et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007, 80:18-27.
18. Bérard A., Rey E., Oraichi D. Effect of smoking cessation interventions during pregnancy on the newborn. Pharmacoepidemiol Drug Saf 2007, 16:S133.
19. Bergink V., Bouvy P.F., Vervoort J.S., et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 2012, 169:609-615.
20. Biswas P.N., Wilton L.V., Pearce G.L., et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacology 2001, 15:265-271.
21. Blencowe H., Cousens S., Modell B., et al. Folic acid to reduce neonatal mortality from neural tube disorders. Int J Epidemiol 2010, 39:i110-i121.
22. Bodén R., Lundgren M., Brandt L., et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiat 2012, 69:715-721.
23. Bodén R., Lundgren M., Brandt L., et al. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ 2012, 345:e7085.
24. Bolte A.C., van Eyck J., Bruinse H.W., et al. Ketanserin versus dihydralazine in the management of early-onset pre-eclampsia: maternal and neonatal outcome. Am J Obstet Gynecol 1997, 176:15.
25. Bonnot O., Vollset S.E., Godet P.F., et al. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. J Clin Psychopharmacol 2001, 21:456-458.
26. Boucher N., Koren G., Beaulac-Baillargeon L. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 2009, 31:404-409.
27. Bromiker R., Kaplan M. Apparent intrauterine fetal withdrawal from clomipramine hydrochloride. JAMA 1994, 272:1722-1723.
28. Brunner E., Falk D.M., Jones M., et al. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 2013, 14:38.
29. Carmichael S.L., Shaw G.M., Yang W., et al. Maternal stressful life events and risks of birth defects. Epidemiology 2007, 18:356-361.
30. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142:402-408.
31. Casper R.C., Gilles A.A., Fleisher B.E., et al. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology 2011, 217:211-219.
32. Chambers C.D., Hernandez-Diaz S., van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:579-587.
33. Chun-Fai-Chan B., Koren G., Fayez I., et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005, 192:932-936.
34. Clark C.T., Klein A.M., Perel J.M., et al. Lamotrigine dosing for pregnant patients with bipolar disorder 2013, 170:1240-1247.
35. Cohen L.S., Friedman J.M., Jefferson J.W., et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994, 271:146-150.
36. Cole J.A., Ephross S.A., Cosmatos I.S., Walker A.M. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:1075-1085.
37. Cole J.A., Modell J.G., Haight B.R., et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:474-484.
38. Colvin L., Slack-Smith L., Stanley F.J., et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011, 91:142-152.
39. Coppen S., Chaudhry, Swade C. Folic acid enhances lithium prophylaxis. J Affect Dis 1986, 10:9-13.
40. Coppola D. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007, 30:247-264.
41. Croen L.A., Grether J.K., Yoshida C.K., et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011, 68:1104-1112.
42. Czeizel A.E., Rockenbauer M., Sørensen H.A.T., et al. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicol Teratol 2004, 26:593-598.
43. Davis R.L., Rubanowice D., McPhillips H., et al. HMO Research Network Center for Education, Research in Therapeutics: Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007, 16:1086-1094.
44. Di Gianantonio E. Venlafaxine in pregnancy: A prospective controlled study. Reprod Toxicol 2006, 22:269.
45. Diav-Citrin O., Okotore B., Lucarelli K., et al. Pregnancy outcome following first-trimester exposure to zopiclone: a prospective controlled cohort study. Am J Perinatol 1999, 16:157-160.
46. Diav-Citrin O., Shechtman S., Aharonovich A., et al. Pregnancy outcome after gestational exposure to loratadine or other antihistamines: a prospective controlled cohort study. J Allergy Clin Immunol 2003, 111:1239-1243.
47. Diav-Citrin O., Shechtman S., Ornoy S., et al. The safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005, 66:317-322.
48. Diav-Citrin O., Shechtman S., Weinbaum D., et al. Paroxetine and fluoxetine in pregnancy: a prospective, multi-center, controlled, observational study. Br J Clin Pharmacol 2008, 65:695-705.
49. Diav-Citrin O. Pregnancy outcome after in-utero exposure to lithium: a prospective controlled cohort study. Birth Defects Res A Clin Mol Teratol 2006, 76:424.
50. Djulus J., Koren G., Einarson T.R., et al. Exposure to mirtazapine during pregnancy: a prospective comparative study of birth outcomes. J Clin Psychiatry 2006, 67:1280-1284.
51. Dolovich L.R., Addis A., Vaillancourt Regis, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998, 317:839-843.
52. Dostal M., Weber-Schoendorfer C., Sobesky J., Schaefer C. Pregnancy outcome following use of levodopa, pramipexole, ropinirole and rotigotine for restless legs syndrome during pregnancy: a case series. Eur J Neurol 2013, 20:1241-1246.
53. Dubnov-Raz G., Juurlink D.N., Fogelman R., et al. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008, 122:e710-e715.
54. Duijvestijn Y.C.M., Kalmeijer M.D., Passier A.L.M., et al. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine. Br J Clin Pharmacol 2003, 56:581-582.
55. Dunkel Schetter C., Tanner L. Anxiety, depression and stress in pregnancy: implications for mothers, children, research, and practice. Curr Opin Psychiatry 2012, 20:141-148.
56. Einarson A., Bailey B., Jung G., et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997, 78:183-186.
57. Einarson A., Bonari L., Voyer-Lavigne S., et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 2003, 48:106-110.
58. Einarson A., Pistelli A., de Santis M., et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008, 165:749-752.
59. El Marroun H., Jaddoe V.W., Hudziak J.J., et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012, 69:706-714.
60. Ellfolk M., Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010, 30:249-260.
61. Enato E., Moretti M., Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can 2011, 33:46-48.
62. Ericson A., Källén B., Wiholm B.E. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55:503-508.
63. Eros E., Czeizel A.E., Rockenbauer M., et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolam and clonazepam treatment during pregnancy. European J Obstet Gynecol Reprod Biol 2002, 101:147-154.
64. Eyding D., Lelgemann M., Grouven U., et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010, 341:c4737.
65. Figueroa R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr 2010, 31:641-648.
66. Frassetto F., Martel F.T., Barjhoux C.E., et al. Goiter in a newborn exposed to lithium in utero. Ann Pharmacother 2002, 36:1745-1748.
67. Freeman M.P., Nolan P.E., Davis M.F., et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008, 28:646-653.
68. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010, 36:518-544.
69. Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Expert Opinion on Drug Safety 2012, 11:425-437.
70. Gentile S., Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011, 128:1-9.
71. Gidai J., Acs N., Banhidy F., et al. No association found between use of very large doses of diazepam by 112 pregnant women for a suicide attempt and congenital abnormalities in their offspring. Toxicol Ind Health 2008, 24:29-39.
72. Gidai J., Acs N., Bánhidy F., et al. A study of the teratogenic and fetotoxic effects of large doses of chlordiazepoxide used for self-poisoning by 35 pregnant women. Toxicol Ind Health 2008, 24:41-51.
73. Gidai J., Acs N., Banhidy F., et al. An evaluation of data for 10 children born to mothers who attempted suicide by taking large doses of alprazolam during pregnancy. Toxicol Ind Health 2008, 24:53-60.
74. Gidai J., Acs N., Bánhidy F., et al. Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam. Pharmacoepidemiol Drug Saf 2010, 19:175-182.
75. Goldstein D.J., Corbin L.A., Fung M.C. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000, 20:399-403.
76. Gracious B.L., Wisner K.L. Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. Depress Anxiety 1997, 6:124-128.
77. Greer L.G., Sheffield J.S., Rogers V.L., et al. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol 2010, 115:711-716.
78. Grigoriadis S., VonderPorten E.H., Mamisashvili L. Antidepressant exposure during pregnancy and congenital malformations: is there an associatioin? A systematic review and meta-analysis of the best evidence. J Clin Psychiat 2013, 74:e293-e308.
79. Grigoriadis S., Vonderporten E.H., Mamisashvili L., et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014, 358:f6932.
80. Grote N.K., Bridge J.A., Gavin A.R., et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Phychiatry 2010, 67:1012-1024.
81. Grote V., Vik T., von Kries R., et al. Maternal postnatal depression and child growth: a European cohort study. BMC Pediatr 2010, 10:14.
82. Grzeskowiak L.E., Gilbert A.L., Morrison J.L. Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight. J Dev Orig Health Dis 2012, 3:253-261.
83. Guclu S., Gol M., Dogan E., et al. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Arch Gynecol Obstet 2005, 272:298-300.
84. Habermann F., Fritzsche J., Fuhlbrück F., et al. Atypical antipsychotic drugs and pregnancy outcome: A prospective cohort study. J Clin Psychopharmacol 2013, 33:453-462.
85. Hallberg P., Sjöblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breastfeeding: a review and clinical aspects. J Clin Pharmacol 2005, 25:59-73.
86. Han M., Neves A.L., Serrano M., et al. Effects of alcohol, lithium, and homocysteine on nonmuscle myosin-II in the mouse placenta and human trophoblasts. Am J Obstet Gynecol 2012, 207(140):e7-19.
87. Hanley G.E., Brain U., Oberlander T.F. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect. Early Hum Dev 2013, 89:519-524.
88. Harder T., Rodekamp E., Schellong K., et al. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 2007, 165:849-857.
89. Heinonen O.P., Slone D., Dick L.M., et al. Birth Defects and Drugs in Pregnancy. Littleton/USA: Publishing Sciences Group 1977.
90. Hendrick V., Stow Z.N., Altshuler L.L. Placental passage of antidepressant medications. Am J Psychiatry 2003, 160:993-996.
91. Hilli J., Heikkinen T., Rontu R., et al. MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol 2009, 19:363-370.
92. Hoog S.L., Cheng Y., Elpers J., Dowsett S.A. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci 2013, 10:413-419.
93. Hoppenbrouwers C.J., Bosma J., Wennink H.J., et al. Neonatal seizures on EEG after in utero exposure to venlafaxine. Br J Clin Pharmacol 2010, 70:454-456.
94. Hviid A., Melbye M., Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med 2013, 369:2406-2415.
95. Jacobson S.J., Jones K., Johnson K., et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992, 339:530-533.
96. Jimenez-Solem E., Andersen J.T., Petersen M., et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012, 2:e001148.
97. Johnson K.C., LaPrairie J.L., Brennan P.A., et al. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 2012, 69:787-794.
98. Juric S., Newport D.J., Ritchie J.C., et al. Zolpidem (Ambien) in pregnancy: placental passage and outcome. Arch Womens Ment Health 2009, 12:441-446.
99. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004, 158:312-316.
100. Källén B. The problem of confounding in studies of the effects of maternal drug user on pregnancy outcome. Obstet Gynecol Int 2012, 148616.
101. Källén B., Olausson P.O. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008, 17:801-806.
102. Källén B., Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A 2007, 79:301-308.
103. Kennedy D.S., Evans M., Wand I., Webster W.F. Fetal abnormalities with high-dose tranylcypromine in two consecutive pregnancies {Abstract}. Teratology 2001, 64:324.
104. Kieler H., Artama M., Engeland A., et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012, 344:d8012.
105. Kim D.R., Epperson N., Paré E., et al. An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorder. J Women's Health 2011, 20:255-261.
106. Kirchheiner J., Berghöfer A., Bolk-Weischedel D. Healthy outcome under olanzapine -treatment in a pregnant woman. Pharmacopsychiatry 2000, 33:78-80.
107. Kirk L., Jorgensen A. Concentrations of Cis(Z)-flupentixol in maternal serum, amniotic fluid, umbilical cord serum, and milk. Psychopharmacology 1980, 72:107-108.
108. Klieger-Grossmann C., Weitzner B., Panchaud A., et al. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J Clin Pharmacol 2012, 52:766-770.
109. Kornum J.B., Nielsen R.B., Pedersen L., et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010, 2:29-36.
110. Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: Another clinical report and a review of the literature. Am J Med Genet 2005, 132A:441-444.
111. Kris E.B. Children born to mothers maintained on pharmacotherapy during pregnancy and postpartum. Recent Adv Biol Psychiatr 1961, 4:180-187.
112. Kris E.B. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 1965, 7:785-789.
113. Kusakawa S., Yamauchi J., Miyamoto Y., et al. Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. Life Sci 2008, 83:871-877.
114. Laegreid L., Hagberg G., Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines - a prospective study. Neuropediatrics 1992, 23:60-67.
115. Laegreid L., Olegard R., Walstrom J., et al. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1989, 114:126-131.
116. Laine K.L., Heikkinen T., Ekblad U., et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60:720-726.
117. Lattimore K.A., Donn S.M., Kaciroti N., et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005, 25:595-604.
118. Lennestål R., Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007, 27:607-613.
119. Leventhal K., Byatt N., Lundquist R. Fetal cardiac arrhythmia during bupropion use. Acta Obstet Gynecol Scand 2010, 89:980-981.
120. Levinson A.J., Zipursky R.B. Antipsychotics and the treatment of women with psychosis. Handbook of Female Psychopharmacology 2003, 63. Dunitz, London. M. Steiner, G. Koren (Eds.).
121. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
122. Lim K., Sanders A., Brain U., et al. Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum Dev 2012, 88:609-615.
123. Lin A.E., Peller A.J., Westgate M.N., et al. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A 2004, 70:534-536.
124. Llewellyn A., Stowe Z.N., Strader J.R. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998, 59:57-64.
125. Loughhead A.M., Fisher A.D., Newport D.J., et al. Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 2006, 163:145-147.
126. Loughhead A.M., Stowe Z.N., Newport D.J., et al. Placental passage of tricyclic antidepressants. Biol Psychiatry 2006, 59:287-290.
127. Louik C., Lin A.E., Werler M.M., et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007, 356:2675-2683.
128. Lutz U.C., Hiemke C., Wiatr G., et al. Aripiprazole in pregnancy and lactation: A case report. J Clin Psychopharmacol 2010, 30:204-205.
129. Maayan-Metzger A., Kuint J., Lubetsky A., et al. Maternal selective serotonin reuptake inhibitor intake does not seem to affect neonatal platelet function tests. Acta Haematol 2006, 115:157-161.
130. Malek-Ahmadi P. Olanzapine in pregnancy. Ann Pharmacother 2001, 35:1294-1295.
131. Malm H., Artama M., Gissler M., et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011, 118:111-120.
132. Malzacher A., Engler H., Drack G., et al. Lethargy in a newborn: lithium toxicity or lab error?. J Perinat Med 2003, 31:340-342.
133. Manber R., Schnyer R.N., Lyell D., et al. Acupuncture for depression during pregnancy: a randomized controlled trial. Obstet Gynecol 2010, 115:511-520.
134. McElhatton P.R., Garbis H.M., Eléfant E., et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996, 10:285-294.
135. McElhatton P.R. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994, 8:461-475.
136. McKenna K., Einarson A., Levinson A., et al. Significant changes in antipsychotic drug use during pregnancy. Vet Human Toxicol 2004, 46:44-46.
137. McKenna K., Koren G., Tetelbaum M., et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005, 66:444-449.
138. Mendhekar D.N., Sunder K.R., Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord 2006, 8:299-300.
139. Mendhekar D.N., War L., Sharma J.B., et al. Olanzapine and pregnancy. Pharmacopsychiatry 2002, 35:122-123.
140. Merlob P., Birk E., Sirota L., et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009, 85:837-841.
141. Mhanna M.J., Bennett J.B., Izatt S.D. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997, 100:158-159.
142. Milkovich L., van den Berg B.J. Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 1974, 291:1268-1271.
143. Morrell M.J. Folic acid and epilepsy. Epilepsy Curr 2002, 2:31-34.
144. Moses-Kolko E.L., Bogen D., Perel J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 2005, 293:2372-2383.
145. Myles N. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust NZ J Psychiatry 2013, 47:1002-1012.
146. Nageotte M.P., Briggs G.G., Towers C.V., et al. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am J Obstet Gynecol 1996, 174:1801-1805.
147. Nagy A., Tenyi T., Lenard K., et al. Olanzapine and pregnancy. Orv Hetil 2001, 142:137-138.
148. Neumann N.U., Frasch K. Olanzapin und Schwangerschaft. Nervenarzt 2001, 72:876-878.
149. Newham J.J., Thomas S.H., MacRitchie K., et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008, 192:333-337.
150. Newport D.J., Viguera A.C., Beach A.J., et al. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry 2005, 162:2162-2170.
151. Nordeng H., Gelder M., Spigset O., et al. Antidepressant exposure, maternal depression and pregnancy outcome - results from the Norwegian mother and child cohort study {Abstract}. Reprod Toxicol 2011, 31:263.
152. Nulman I., Koren G., Rovet J., et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012, 169:1165-1174.
153. Nulman I., Rovet J., Stewart D.E., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002, 159:1889-1895.
154. Nulman I., Rovet J., Stewart D.E., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997, 336:258-262.
155. Oberlander T.F., Papsdorf M., Brain U.M., et al. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 2010, 164:444-451.
156. Oberlander T.F., Warburton W., Misri S., et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008, 83:68-76.
157. Occhiogrosso M., Omran S.S., Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiat 2012, 169:134-140.
158. Palmsten K., Hernández-Díaz S., Huybrechts K.F. Use of antidepressants near delivery and risk of postpartum haemorrhage: cohort study of low income women in the United States. BMJ 2013, 347:f4877.
159. Palmsten K., Huybrechts K.F., Michels K.B., et al. Antidepressant use and risk for preeclampsia. Epidemiology 2013, 24:682-691.
160. Palmsten K., Setoguchi S., Margulis A.V., et al. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?. Am J Epidemiol 2012, 175:988-997.
161. Patel S.R., Wisner K.L. Decision making for depression treatment during pregnancy and the postpartum period. Depress Anxiety 2011, 28:589-595.
162. Pawluski J.L. Perinatal selective serotonin reuptake inhibitor exposure: impact on brain development and neural plasticity. Neuroendocrinology 2012, 95:39-46.
163. Pearson K.H., Nonacs R.M., Viguera A.C., et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007, 68:1284-1289.
164. Pearson R.M., Evans J., Kounali D., et al. Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry 2013, 70:1312-1319.
165. Pedersen L.H., Henriksen T.B., Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010, 125:e600-e608.
166. Pedersen L.H., Henriksen T.B., Vestergaard M., et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009, 339:b3569.
167. Peinemann F., Daldrup T. Severe and prolonged sedation in five neonates due to persistence of active diazepam metabolites. Eur J Pediatr 2001, 160:378-381.
168. Peitl R.V. Ziprasidone as a possible cause of cleft palate in a newborn. Psychiatria Danubina 2010, 22:117-119.
169. Petik D., Acs N., Bánhidy F., et al. A study of the potential teratogenic effect of large doses of promethazine used for a suicide attempt by 32 pregnant women. Toxicol Ind Health 2008, 24:87-96.
170. Pinelli J.M., Symington A.J., Cunningham K.A., et al. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 2002, 187:245-249.
171. Polen K.N., Rasmussen S.A., Riehle-Colarusso T., Reefhuis J. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007. National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2013, 97:28-35.
172. Pottegård A., Hallas J., Andersen J.T., et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry 2014, 75:e88-e93.
173. Rai D., Lee B.K., Dalman C., et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 2013, 346:f2059.
174. Rampono J., Simmer K., Ilett K.F., et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009, 42:95-100.
175. Reis M., Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010, 40:1723-1733.
176. Reis M., Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008, 28:279-288.
177. Riggin L., Frankel Z., Moretti M., et al. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can 2013, 35:362-369. Erratum appears in J Obstet Gynaecol Can 2013; 35: 691.
178. Robakis T., Williams K.E. Atypical antipsychotics during pregnancy: Make decisions based on available evidence, individualized risk/benefit analysis. Curr Psychiat 2013, 12:12-18.
179. Rohde A., Dembinski J., Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet 2003, 268:219-221.
180. Rybakowski J.K. Moclobemide in pregnancy. Pharmacopsychiatry 2001, 34:82-83.
181. Saks B.R. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient. A report of 7 cases. Arch Womens Ment Health 2001, 3:165-170.
182. Salisbury A.L., Wisner K.L., Pearlstein T., et al. Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment. Depress Anxiety 2011, 28:1008-1019.
183. Salkeld E., Ferris L.E., Juurlink D.N. The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants. J Clin Psychopharmacol 2008, 28:230-234.
184. Salvia-Roiges G.L., Gonce-Mellgren A., Esque-Ruiz M.T., et al. Neonatal convulsions and subarachnoidal hemorrhage after in utero exposure to paroxetine. Rev Neurol 2003, 36:724-726.
185. Sanz E.J., De-las-Cuevas C., Kiuru A., et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005, 365:482-487.
186. Sari Y., Zhou F.C. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 2003, 21:417-424.
187. Schimmell M.S., Katz E.Z., Shaag Y., et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991, 29:479-484.
188. Schou M. What happened later to the lithium babies?. Arch Psychiar Scand 1976, 54:193-197.
189. Shepard T.H., Brent R.L., Friedman J.M., et al. Update on new developments in the study of human teratogens. Teratology 2002, 65:153-161.
190. Simon G.E., Cunningham M.L., Davis R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002, 159:2055-2061.
191. Sit D., Luther J., Dills J.L.J., et al. Abnormal screening for gestational diabetes, maternal mood disorder, and preterm birth. Bipolar Dis 2013, 10.1111/bdi.12129.
192. Sit D., Perel J.M., Luther J.F., et al. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. J Clin Psychopharmacol 2010, 30:381-386.
193. Sit D.K., Perel J.M., Helsen J.C., et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008, 69:652-658.
194. Fluvoxamine Sivojelezova A. (LUVOX™) use in pregnancy. Clin Pharmacol Ther 2004, 75:25.
195. Sivojelezova A., Shuhaiber S., Sarkissian L., et al. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005, 193:2004-2009.
196. Slone D., Siskind V., Heinonen O.P. Antenatal exposure to the phenothiazines in relatin to congenital malformations, parinatal mortality rate, birth weight and intelligence quotient score. Am J Obsetr Gynecol 1977, 128:486-488.
197. Sobel D.E. Fetal damage due to ECT, insulin coma, chlorpromaine, or reserpine. Arch Gen psych 1960, 2:606-611.
198. Sora S., Agostini Carbone M.L. Chloral hydrate, methylmercury hydroxide and ethidium bromide affect chromosome segregation during meiosis of Saccharomyces cerevisiae. Mutat Res 1987, 190:13-17.
199. Sørensen M.J., Grønborg T.K., Christensen J., et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013, 5:449-459.
200. Spinelli M.G. Interpersonal psychotherapy for depressed antepartum women: a pilot study. Am J Psychiatry 1997, 154:1028-1030.
201. Stephens S., Wilson G., Gilfillan C., et al. Preliminary data on therapeutic exposure to zopiclone during pregnancy. Reprod Toxicol 2008, 26:73-74.
202. Steyn D.W., Odendaal H.J. The effect of oral ketanserin on fetal heart rate parameters. J Matern Fetal Investig 1998, 8:126-129.
203. Stika C., Frederiksen M. Drug therapy in pregnant and nursing women. Principles of Clinical Pharmacology 2001, 227-291. Academic Press, San Diego. A.J. Atkinson, C.E. Daniels, R. Dedrick, C.V. Grudzinskas (Eds.).
204. Tabacova S.A., McCloskey C.A., Fisher J.E. Adverse developmental events reported to FDA in association with maternal citalopram treatment in pregnancy. Birth Defects Res A 2004, 70:361.
205. Tanaka T., Choi J., Nomura Y., et al. The incidence of poor neonatal adaptation syndrome following exposure to venlafaxine in late pregnancy. Birth Defects Res A Clin Mol Teratol 2007, 79:446.
206. Taylor T., Kennedy D. Safety of moclobemide in pregnancy and lactation, four case reports. Birth Defects Res A Clin Mol Teratol 2008, 82:413.
207. Taylor T.M., O'Toole M.S., Ohlsen R.I., et al. Safety of quetiapine during pregnancy. Am J Psychiatry 2003, 160:588-589.
208. Tegethoff M., Greene N., Olsen J., et al. Stress during pregnancy and offspring pediatric disease: A National Cohort Study. Health Perspect 2011, 119:1647-1652.
209. Tényi T., Trixler M., Keresztes Z. Quetiapine and pregnancy. Am J Psychiatry 2002, 159:674.
210. ter Horst PG, van der Linde S., Smit J.P., et al. Clomipramine concentration and withdrawal symptoms in 10 neonates. Br J Clin Pharmacol 2012, 73:295-302.
211. Treichel M., Schwendener Scholl K., Kessler U., et al. Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis?. World J Pediatr 2009, 5:65-67.
212. Turcotte V., Ferreira E., Duperron L. Utilité du dropéridol et de la diphenhydramine dans l'hyperemesis gravidarum. J Soc Obstet Gynaecol Can 2001, 23:133-139.
213. van der Lugt N.M., van de Maat J.S., van Kamp I.L., et al. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies 2012, 88:375-378.
214. Van Vaes A., van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1969, 9:224-227.
215. Ververs F.F., Voorbij H.A., Zwarts P., et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 2009, 48:677-683.
216. Viguera A.C., Nonacs R., Cohen L.S., et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000, 157:179-184.
217. Vladimir J., Dragan M., Ružić, et al. Zuclopenthixol decanoate in pregnancy: successful outcomes in two consecutive offsprings of the same mother. Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journal of Serbia & Montenegro 2013, 70:526-529.
218. Wajnberg R., Diav-Citrin O., Shechtman S., et al. Pregnancy outcome after in-utero exposure to methylphenidate: A prospective comparative cohort study (abstract). Reprod Toxicol 2011, 31:267.
219. Wang L.H., Lin H.C., Lin C.C., et al. Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin Pharmacol Ther 2010, 88:369-374.
220. Warburton W., Hertzman C., Oberlander T.F. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010, 121:471-479.
221. Wichman C.L., Moore K.M., Lang T.R., et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009, 84:23-27.
222. Wikner B.N., Källén B. Are hypnotic benzodiazepine receptor agonists teratogenic in humans?. J Clin Psychopharmacol 2011, 31:356-359.
223. Wikner B.N., Stiller C.O., Bergman U., et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007, 16:1203-1210.
224. Wikner B.N., Stiller C.O., Källén B., et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf 2007, 16:988-994.
225. Williams S.F., Alvarez J.R., Pedro H.F., et al. Glutaric aciduria type II and narcolepsy in pregnancy. Obstet Gynecol 2008, 111:522-524.
226. Wilson K.L., Zelig C.M., Harvey J.P., et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011, 28:19-24.
227. Wirz-Justice A., Bader A., Frisch U., et al. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. J Clin Psychiatry 2011, 72:986-993.
228. Wisner K.L., Bogen D.L., Sit D., et al. Does fetal exposure to SSRIs or maternal depression impact infant growth?. Am J Psych 2013, 170:485-493.
229. Wisner K.L., Perel J.M., Wheeler S.B. Tricyclic dose requirements across pregnancy. Am J Psychiat 1993, 150:1541-1542.
230. Wisner K.L., Sit D.K., Hanusa B.H., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166:557-566.
231. Wisner K.L., Sit D.K., Moses E.L. Antipsychotic treatment during pregnancy: A model for decision making. Adv Schizophr Clin Psychiatry 2007, 3:48-55.
232. Wurst K.E., Poole C., Ephross S.A., et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010, 88:159-170.
233. Yacobi S., Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies?. Isr J Psychiatry Relat Sci 2008, 45:95-106.
234. Yogev Y., Ben-Haroush A., Kaplan B. Maternal clozapine treatment and decreased fetal heart rate variability. Int J Gynecol Obstet 2002, 79:259-260.
235. Yonkers K.A., Wisner K.L., Stowe Z., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004, 161:608-620.
236. Zalzstein E., Koren G., Einarson T., et al. A case-control study on the association between first trimester exposure to lithium and Ebstein's anomaly. Am J Cardiol 1990, 65:817-818.
237. Zegers B., Andriessen P. Maternal lithium therapy and neonatal morbidity. Eur J Pediatr 2003, 162:348-349.
238. Zeskind P.S., Stephens L.E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004, 113:368-375.